5-丁基海因酸 | 63059-33-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 5-丁基海因酸
• 英文名称: (butylcarbamoyl)glycine
• 英文别名: N-n-butyl-hydantoic acid；N-butyl-N'-(carboxymethyl)urea；N-[(butylamino)carbonyl]glycine；Glycine, N-[(butylamino)carbonyl]-；2-(butylcarbamoylamino)acetic acid
• CAS: 63059-33-6
• 化学式: C₇H₁₄N₂O₃
• 分子量: 174.2
• InChiKey: KGWHMDCQVDMTNZ-UHFFFAOYSA-N

物化性质

• 熔点：
  140 °C
• 沸点：
  305.17°C (rough estimate)
• 密度：
  1.2227 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924199090
• 储存条件：
  存放于阴凉干燥处。

SDS

Name:	5-Butylhydantoic acid 98% (titr.) Material Safety Data Sheet
Synonym:	None
CAS:	63059-33-6

Section 1 - Chemical Product MSDS Name:5-Butylhydantoic acid 98% (titr.) Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
63059-33-6	Glycine, n-(butylamino)carbonyl-	98.0	263-811-0

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 63059-33-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 140 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H14N2O3
Molecular Weight: 174.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 63059-33-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Glycine, n-(butylamino)carbonyl- - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 63059-33-6: No information available.
Canada
CAS# 63059-33-6 is listed on Canada's NDSL List.
CAS# 63059-33-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 63059-33-6 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-丁基海因酸 在 lithium hydroxide 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 生成 (Z)-7-((1S,2R,3R,4R)-3-{[2-(3-Butyl-ureido)-acetylamino]-methyl}-7-oxa-bicyclo[2.2.1]hept-2-yl)-hept-5-enoic acid
  参考文献：
  名称：

  7-氧杂双环[2.2.1]庚基羧酸作为血栓烷A2拮抗剂：氮杂欧米茄链类似物。

  摘要：

  新型的双环前列腺素类似物，[1S- [1 alpha，2 alpha（Z），3 alpha，4 alpha]]-7- [3-[[[[[（[Oxoheptyl）amino] acetyl] amino] -methyl]发现-7-氧杂双环[2.2.1]庚-2-基] -5-庚烯酸[-]-7是有效的选择性血栓烷A2（TxA2）受体拮抗剂。与相关系列的ω-链烯丙基醇不同，酰胺7及其同类物在体外（牛冠状动脉）和体内（麻醉的豚鼠）均一致没有直接收缩活性。酰胺7有效抑制（a）花生四烯酸诱导的人血小板丰富血浆的血小板聚集（I50 = 0.18 +/- 0.006 microM），（b）11,9-环氧甲氧基-PGH2诱导的人血小板血小板聚集-血浆（I50 = 0.24 microM），（c）11,9-环氧甲氧基-PGH2诱导的豚鼠气管（Kb = 3.0 +/- 0.3 nM）或大鼠主动脉（Kb = 8.8 +/-

  DOI：

  10.1021/jm00171a021
• 作为产物：
  描述：

  N-butyl-N'-<(ethoxycarbonyl)methyl>urea 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以97%的产率得到5-丁基海因酸
  参考文献：
  名称：

  7-氧杂双环[2.2.1]庚基羧酸作为血栓烷A2拮抗剂：氮杂欧米茄链类似物。

  摘要：

  新型的双环前列腺素类似物，[1S- [1 alpha，2 alpha（Z），3 alpha，4 alpha]]-7- [3-[[[[[（[Oxoheptyl）amino] acetyl] amino] -methyl]发现-7-氧杂双环[2.2.1]庚-2-基] -5-庚烯酸[-]-7是有效的选择性血栓烷A2（TxA2）受体拮抗剂。与相关系列的ω-链烯丙基醇不同，酰胺7及其同类物在体外（牛冠状动脉）和体内（麻醉的豚鼠）均一致没有直接收缩活性。酰胺7有效抑制（a）花生四烯酸诱导的人血小板丰富血浆的血小板聚集（I50 = 0.18 +/- 0.006 microM），（b）11,9-环氧甲氧基-PGH2诱导的人血小板血小板聚集-血浆（I50 = 0.24 microM），（c）11,9-环氧甲氧基-PGH2诱导的豚鼠气管（Kb = 3.0 +/- 0.3 nM）或大鼠主动脉（Kb = 8.8 +/-

  DOI：

  10.1021/jm00171a021

文献信息

• Bicycloheptane substituted diamide and its congener prostaglandin analogs
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04734424A1

  公开（公告）日：1988-03-29

  Bicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; Q is --CH.dbd.CH--, --CH.sub.2 --, ##STR2## or a single bond; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR3## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, lower alkyl-S-, aryl-S-, arylalkyl-S-, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

  提供了具有结构式##STR1##的双环庚烷取代酰胺前列腺素类似物，其中m为0至4；A为--CH.dbd.CH--或--CH.sub.2 --CH.sub.2 --；n为1至5；Q为--CH.dbd.CH--，--CH.sub.2 --，##STR2##或单键；R为CO.sub.2 H，CO.sub.2烷基，CO.sub.2碱金属，CO.sub.2多羟胺盐，--CH.sub.2 OH，##STR3##其中R.sup.4和R.sup.5相同或不同，为H，低烷基，羟基，低烷氧基或芳基，R.sup.4和R.sup.5中至少有一个不是羟基和低烷氧基；p为1至4；R.sup.1为H或低烷基；q为1至12；R.sup.2为H或低烷基；R.sup.3为H，低烷基，低烯基，低炔基，芳基，芳基烷基，低烷氧基，芳氧基，芳基烷氧基，氨基，烷基氨基，芳基氨基，芳基烷基氨基，低烷基-S-，芳基-S-，芳基烷基-S-，##STR4##（其中n'为0，1或2），烷基氨基烷基，芳基氨基烷基，芳基烷基氨基烷基，烷氧基烷基，芳氧基烷基或芳基烷氧基。这些化合物是心血管药物，例如，在治疗血栓性疾病中有用。
• 7-oxabicycloheptane substituted diamide and its congener prostaglandin
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04663336A1

  公开（公告）日：1987-05-05

  7-Oxabicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; Q is --CH.dbd.CH--, --CH.sub.2 --, ##STR2## or a single bond; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR3## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

  提供了具有结构式##STR1##的7-氧代双环庚烷取代酰胺前列腺素类似物，其中m为0至4；A为--CH.dbd.CH--或--CH.sub.2 --CH.sub.2 --；n为1至5；Q为--CH.dbd.CH--，--CH.sub.2 --，##STR2##或单键；R为CO.sub.2 H，CO.sub.2烷基，CO.sub.2碱金属，CO.sub.2多羟胺盐，--CH.sub.2 OH，##STR3##其中R.sup.4和R.sup.5相同或不同，为H，低烷基，羟基，低烷氧基或芳基，R.sup.4和R.sup.5中至少有一个不是羟基和低烷氧基；p为1至4；R.sup.1为H或低烷基；q为1至12；R.sup.2为H或低烷基；R.sup.3为H，低烷基，低烯基，低炔基，芳基，芳基烷基，低烷氧基，芳氧基，芳基烷氧基，氨基，烷基氨基，芳基氨基，芳基烷基氨基，##STR4##（其中n'为0，1或2），烷基氨基烷基，芳基氨基烷基，芳基烷基氨基烷基，烷氧基烷基，芳氧基烷基或芳基烷氧基。这些化合物是心血管药物，例如，在治疗血栓性疾病方面有用。
• 7-thiabicycloheptane substituted diamide and its congener prostaglandin
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04735962A1

  公开（公告）日：1988-04-05

  7-Thiabicycloheptane substituted diamide and congener prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 1 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR2## wherein R.sup.3 and R.sup.4 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.3 and R.sup.4 being other than hydroxy and lower alkoxy; p is 1 to 4; Z is ##STR3## q is 1 to 12; R.sup.1 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

  提供了7-硫代双环庚烷取代二酰胺和同系物前列腺素类似物，其具有结构式##STR1##其中m为1至4；A为--CH.dbd.CH--或--CH.sub.2 --CH.sub.2 --；n为1至5；R为CO.sub.2 H，CO.sub.2烷基，CO.sub.2碱金属，CO.sub.2多羟胺盐，--CH.sub.2 OH，##STR2##其中R.sup.3和R.sup.4相同或不同，为H，低烷基，羟基，低烷氧基或芳基，R.sup.3和R.sup.4中至少有一个不是羟基和低烷氧基；p为1至4；Z为##STR3##q为1至12；R.sup.1为H或低烷基；R.sup.3为H，低烷基，低烯基，低炔基，芳基，芳基烷基，低烷氧基，芳氧基，芳基烷氧基，氨基，烷基氨基，芳基氨基，芳基烷基氨基，##STR4##（其中n'为0、1或2），烷基氨基烷基，芳基氨基烷基，芳基烷基氨基烷基，烷氧基烷基，芳氧基烷基或芳基烷氧基。这些化合物是心血管药物，例如，在治疗血栓性疾病中有用。
• BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE
  申请人：Fujita Takashi

  公开号：US20130165446A1

  公开（公告）日：2013-06-27

  The present invention addresses the problem of finding a compound having both PPAR activation activity and angiotensin receptor antagonistic activity. The present invention is a benzo- or pyrido-imidazole derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, or a ester or amide thereof (where A is biphenyl methyl-imidazolyl, biphenyl methyl-benzimidazolyl, or the like, B is divalent benzimidazolyl or the like, C is carboxyl or the like, E is divalent phenyl, naphthyl, or the like, G is a dangling bond, oxygen, or the like, Q is oxygen or sulfur, n is an integer from 1 to 6, p is an integer from 1 to 6, V is a dangling bond, oxygen, or the like, and R is hydrogen, alkyl, or the like).

  本发明解决了寻找既具有PPAR激活活性又具有血管紧张素受体拮抗活性的化合物的问题。本发明是一种由通式（I）表示的苯并或吡啶-咪唑衍生物，其药学上可接受的盐，或其酯或酰胺（其中A是联苯甲基咪唑基，联苯甲基苯并咪唑基或类似物，B是二价苯并咪唑基或类似物，C是羧基或类似物，E是二价苯基，萘基或类似物，G是悬键，氧或类似物，Q是氧或硫，n是从1到6的整数，p是从1到6的整数，V是悬键，氧或类似物，R是氢，烷基或类似物）。
• TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS
  申请人：NATIONAL YANG-MING UNIVERSITY

  公开号：US20160151362A1

  公开（公告）日：2016-06-02

  The present invention relates to novel TMPK inhibitor and their methods of use. In particular, it relates to novel TMPK inhibitor of Formula (I) and therapeutics that decrease the cellular dTTP level to suppress the growth and inhibit DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.

  本发明涉及一种新型TMPK抑制剂及其使用方法。具体而言，涉及一种新型公式（I）的TMPK抑制剂和治疗剂，可降低细胞dTTP水平以抑制肿瘤细胞的生长和DNA修复，作为一种新型化疗增敏剂，在治疗或预防癌症的方法中有用。